Clinical Trials Logo
  1. Home
  2. Brain Metastases, Adult
  3. NCT05095766

Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis — ITIRR  

Brain Metastases, Adult Clinical Trial

Official title:
Differentiation Between Radionecrosis and Tumor Recurrence for Post-stereotactic Radiosurgery Follow-up by Pharmacokinetic Analyses in Perfusion MRI and Positron Emission Tomography

Clinical Trial Summary

During gamma scalpel treatment of brain tumors and metastases, a follow-up magnetic resonance imaging (MRI) scan is performed. The radiologist who reviews the MRI assesses whether there is an increase in signal at the tumor site. This increase potentially indicates that the treatment was not effective. However, in 25% of cases (one in four people), this signal enhancement is not due to ineffective treatment, but to inflammation (swelling/damage) and tissue death around the tumor. This is why when an increase in signal is detected, additional follow-up is essential. The standard additional follow-up has an accuracy of about 83%. This is an observational study on patients with brain metastatis comparing MRI alone or combined to PET-FET to improve accuracy of diagnosis of metastasis recurrence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05095766
Study type Observational
Source Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Contact
Status Active, not recruiting
Phase
Start date November 23, 2017
Completion date November 23, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05428852 - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases N/A
Recruiting NCT05559853 - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting NCT05689619 - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) N/A
Recruiting NCT04197297 - Brain Imaging Biomarkers in Patients With Brain Metastasis Phase 2
Recruiting NCT04397978 - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated NCT04434560 - Neoadjuvant Immunotherapy in Brain Metastases Phase 2
Recruiting NCT05012254 - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Phase 2
Recruiting NCT05789589 - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT06280300 - Multi-disciplinary Care for Brain Metastases N/A
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Completed NCT03896555 - Intrafractional Head Movement During Radiosurgery
Not yet recruiting NCT06048094 - 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery Phase 1
Terminated NCT03789149 - Focal Intraoperative Radiotherapy of Brain Metastases Phase 2
Recruiting NCT04343157 - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases Phase 2
Recruiting NCT04711824 - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Phase 1/Phase 2
Recruiting NCT05793489 - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin N/A
Recruiting NCT04461418 - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases Phase 2
Recruiting NCT03818386 - Radiotherapy of Multiple Brain Metastases Using AGuIX® Phase 2
Active, not recruiting NCT05087095 - Managing Distress in Malignant Brain Cancer N/A
Recruiting NCT04396717 - Safety Study of Pritumumab in Brain Cancer Phase 1